Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q05397

UPID:
FAK1_HUMAN

ALTERNATIVE NAMES:
Focal adhesion kinase-related nonkinase; Protein phosphatase 1 regulatory subunit 71; Protein-tyrosine kinase 2; p125FAK; pp125FAK

ALTERNATIVE UPACC:
Q05397; B4E2N6; F5H4S4; J3QT16; Q14291; Q8IYN9; Q9UD85

BACKGROUND:
Protein-tyrosine kinase 2, known as Focal adhesion kinase 1, is integral to cell cycle progression, apoptosis, and the reorganization of the actin cytoskeleton. It mediates cell signaling in response to growth factors and integrins, playing a crucial role in neuronal development, osteoblast differentiation, and cardiovascular development. FAK1's activity modulates Rho family GTPases and promotes activation of several signaling pathways, including those involving AKT1 and MAPK.

THERAPEUTIC SIGNIFICANCE:
The exploration of Focal adhesion kinase 1's functions offers promising avenues for drug discovery. Given its central role in numerous physiological processes and signaling pathways, targeting FAK1 could lead to innovative treatments for conditions associated with its dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.